Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares saw unusually-high trading volume on Friday . Approximately 81,619 shares were traded during trading, an increase of 47% from the previous session’s volume of 55,625 shares.The stock last traded at $3.05 and had previously closed at $3.03.

AUPH has been the topic of a number of research reports. Zacks Investment Research downgraded Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, May 5th. Canaccord Genuity reaffirmed a “buy” rating on shares of Aurinia Pharmaceuticals in a research note on Thursday, May 12th. HC Wainwright initiated coverage on Aurinia Pharmaceuticals in a research note on Thursday, June 30th. They set a “buy” rating and a $7.00 price target on the stock. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $7.00 price target on shares of Aurinia Pharmaceuticals in a research note on Wednesday, July 6th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $7.15.

The company has a 50 day moving average price of $2.87 and a 200 day moving average price of $2.63. The company’s market capitalization is $97.83 million.

Aurinia Pharmaceuticals Inc (Aurinia) is a Canada-based is a clinical stage pharmaceutical company. The Company is focused on the development of its therapeutic immunomodulating drug candidate, voclosporin, which is a calcineurin inhibitor (CNI). Voclosporin is an oral drug, administered twice daily.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.